Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 3,917 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: BNT324, Docetaxel, Prednisone/prednisolone; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 21
States / cities: Santa Barbara, California • Aurora, Colorado • Fort Myers, Florida + 17 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 6,608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Erectile Dysfunction, Prostate Cancer
Interventions: Sildenafil 25 MG Oral Tablet, Pentoxifylline, Placebo; Drug · Other
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 30 Years to 89 Years · Male only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Interventions: Prostate cancer screening; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 74 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Androgen Independent Prostate Cancer (AIPC), Non Small Cell Lung Cancer (NSCLC)
Interventions: DN-101 (calcitriol) - Drug; Drug
Lead sponsor: Novacea; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 11
States / cities: Berkeley, California • San Francisco, California • Vallejo, California + 6 more

Conditions: Prostate Cancer
Interventions: Ride Share; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 22 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Castration-Resistant Prostate Cancer
Interventions: Transdermal Testosterone, Standard of Care, Enzalutamide; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic Hormone Refractory Prostate Cancer
Interventions: Patupilone, prednisone, docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 11
States / cities: La Jolla, California • Aurora, Colorado • Norwalk, Connecticut + 8 more

Conditions: Health Status Unknown, Elevated PSA
Interventions: Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, MRI Ultrasound Fusion Guided Biopsy; Procedure · Other · Diagnostic Test
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years and older · Male only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 1 more

Conditions: Prostate Cancer
Interventions: 1.5 T Elekta Unity MR-Linac system, Hydrogel rectal spacer (SpaceOAR); Radiation · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: flexible AIR coil, endorectal coi; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: docetaxel, LHRH agonist, surgery; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 788 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2030
U.S. locations: 221
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more

Conditions: Locally Advanced Prostate Cancer
Interventions: TNFerade™ Biologic; Biological
Lead sponsor: GenVec; Industry
Eligibility: Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Cognitive Affective preparation, General Health Education; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 34 Years to 69 Years · Male only
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hormone Refractory Prostate Cancer
Interventions: LBH589; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Boston, Massachusetts • St Louis, Missouri • Las Vegas, Nevada + 2 more

Conditions: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
Interventions: M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat, Acetaminophen, Ibuprofen, Naproxen, Benadryl, EKG, Bone scan, CT chest, abdomen and pelvis, MRI; Biological · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: AZD3514; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 130 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer
Interventions: Blood Drawing; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Cancer
Interventions: LY3475070, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 50 Years to 79 Years · Male only
Enrollment: 810 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, sargramostim, nilutamide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
Interventions: 18F-fluciclovine, PET/CT; Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced or Metastatic Solid Tumors
Interventions: MDK-703, Checkpoint Inhibitor, Immune; Drug
Lead sponsor: Medikine, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Sarasota, Florida • Huntersville, North Carolina • Austin, Texas + 3 more

Search by objective public record fields.

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

For Cause Prostate Biopsy in REDUCE Population Trial

Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy

Prostate Cancer Genetic Risk Evaluation and Screening Study

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Increasing Access to Definitive Treatment for Prostate Cancer

Testosterone Therapy in Castration Resistant Prostate Cancer

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

TNFerade Biologic to Treat Locally Advanced Prostate Cancer

Facilitating Participation in a Prostate Cancer Risk Assessment Program

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Open Label Prostate Cancer Study

Circulating Tumor Cells in Prostate Cancer Patients

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors